BACE1 and Alzheimer disease: In summary, pre-analytical and analytical protocols for BACE1, as well as other biomarkers for AD, should be harmonized and then standardized at a global scale to drastically reduce inter-study and longitudinal variability and eventually speed up the validation and qualification process of BACE1 biomarker candidates.